ISENTRESS HD Drug Patent Profile
Which patents cover Isentress Hd, and when can generic versions of Isentress Hd launch?
Isentress Hd is a drug marketed by Msd Sub Merck and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges.
The generic ingredient in ISENTRESS HD is raltegravir potassium. Six suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Isentress Hd
A generic version of ISENTRESS HD was approved as raltegravir potassium by HETERO LABS LTD III on December 19th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ISENTRESS HD?
- What are the global sales for ISENTRESS HD?
- What is Average Wholesale Price for ISENTRESS HD?
Summary for ISENTRESS HD
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ISENTRESS HD |
Paragraph IV (Patent) Challenges for ISENTRESS HD
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ISENTRESS HD | Tablets | raltegravir potassium | 600 mg | 022145 | 1 | 2022-10-21 |
| ISENTRESS HD | Tablets | raltegravir potassium | 400 mg | 022145 | 1 | 2011-10-12 |
US Patents and Regulatory Information for ISENTRESS HD
ISENTRESS HD is protected by four US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |
| Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| Msd Sub Merck | ISENTRESS HD | raltegravir potassium | TABLET;ORAL | 022145-002 | May 26, 2017 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ISENTRESS HD
See the table below for patents covering ISENTRESS HD around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 318140 | ⤷ Start Trial | |
| Australia | 2002334207 | ⤷ Start Trial | |
| Brazil | 0213522 | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ISENTRESS HD
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1441735 | DO 67; 3-2008 | Slovakia | ⤷ Start Trial | PRODUCT NAME: RALTEGRAVIR; REGISTRATION NO/DATE: Registration in Community EU/1/07/436/001-002 20071220; FORMER OWNER: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. IT |
| 1441735 | SPC010/2008 | Ireland | ⤷ Start Trial | SPC010/2008: 20091119, EXPIRES: 20221219 |
| 1441735 | 67 3-2008 | Slovakia | ⤷ Start Trial | PRODUCT NAME: RALTEGRAVIR; REGISTRATION NO/DATE: EU/1/07/436/001 - EU/1/07/436/002 20080102 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
